Sangamo Therapeutics (NASDAQ:SGMO) shares traded 12.43% up during most recent session to reach at the closing price of $9.5. The stock exchanged hands 2.15 Million shares versus average trading capacity of 1.71 Million shares, yielding a market cap of $754.21 Million. Wall Street analysts covering the stock are projecting that the stock will reach $11.8 within the next 52-weeks. The mean target projections are based on 5 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Sangamo Therapeutics (NASDAQ:SGMO) high price target of $20 and with a conservative view have low price target of $5.

Wedbush “Downgrades” Sangamo Therapeutics (NASDAQ:SGMO) in a research note issued to investors on 11/01/16 to Neutral.

Additionally on 10/19/16 PiperJaffray “Downgrades” Sangamo Therapeutics (NASDAQ:SGMO) to Neutral and on 8/04/16 Janney Capital “Downgrades” the stock to Neutral. Furthermore on 12/17/15 Janney Capital “Initiates Coverage on” the stock to Buy at $.

On the other hand the company has Relative Strength Index (RSI 14) of 61.76 along with Average True Range (ATR 14) of 0.54, Consequently Sangamo Therapeutics (NASDAQ:SGMO)’s weekly and monthly volatility is 6.69%, 6.29% respectively. The company’s beta value is at 3.26.

In terms of Buy, Sell or Hold recommendations, Sangamo Therapeutics (NASDAQ:SGMO) has analysts’ mean recommendation of 2. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Sangamo Therapeutics (NASDAQ:SGMO)’s minimum EPS for the current quarter is at $-0.29 and can go high up to $0.07. The consensus mean EPS for the current quarter is at $-0.19 derived from a total of 6 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.38 earnings per share for the same quarter during last year.

Previously Sangamo Therapeutics (NASDAQ:SGMO) reported $-0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.26 by $0.03. The company posted an earnings surprise of 11.5%.

Sangamo Therapeutics (NASDAQ:SGMO)’s revenue estimates for the current quarter are $5.98 Million according to 5 number of analysts, for the current quarter the company has high revenue estimates of $10.4 Million in contradiction of low revenue estimates of $4 Million. For the current year the company’s revenue estimates are $20.29 Million compared to low analyst estimates of $18 Million and high estimates of $22.7 Million according to 5 number of analysts.

Currently Sangamo Therapeutics (NASDAQ:SGMO)’s shares owned by insiders are 4.18%, whereas shares owned by institutional owners are 52.8%. However the six-month change in the insider ownership was recorded -0.59%, as well as three-month change in the institutional ownership was recorded 2.01%.

Sangamo Therapeutics (NASDAQ:SGMO) 52-week high price stands at $10.50 and low price stands at $2.65, its price distance from 52-week high is -9.52% while its distance from 52-week low price is 258.49%. The stock hit its 52-week high on 07/14/17, and 52-week low on 12/08/16.

Sangamo Therapeutics (NASDAQ:SGMO)’s trailing twelve month revenues are $18.9 Million, whereas its price to sales ratio for the same period is 39.91. Its book value per share for the most recent quarter is $1.77 while its price to book ratio for the same period is 5.37, as for as the company’s cash per share for the most recent quarter is $1.63, however its price to cash per share ratio for the same period is 5.83. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.